FDA Accepts BLA for Bevacizumab Biosimilar in Solid Tumors and Sets Action Date

Retrieved on: 2021-01-29 17:48:45

Tags for this article:

Click the tags to see associated articles and topics

FDA Accepts BLA for Bevacizumab Biosimilar in Solid Tumors and Sets Action Date. View article details on hiswai:

Excerpt

A Biologics License Application was accepted by the FDA for BAT1706, a monoclonal antibody and proposed biosimilar of bevacizumab, which will be ...

Article found on: www.targetedonc.com